|Table of Contents|

Research progress of neutrophil elastase and cathepsin G in acute promyelocytic leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3118-3122
Research Field:
Publishing date:

Info

Title:
Research progress of neutrophil elastase and cathepsin G in acute promyelocytic leukemia
Author(s):
XIU Ruolin; SUI Meijuan; ZHANG Zhuo; LIU Shuchuan
Department of Hematology,First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China.
Keywords:
acute promyelocytic leukemia; neutrophil elastase; cathepsin G
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2023.16.034
Abstract:
The unique morphological feature of acute promyelocytic leukemia (APL) is that the bone marrow is dominated by promyelocytes with increased granules,and the promyelocytes are rich in azurophilic granules,which contain a large amount of neutrophil elastase (NE) and cathepsin G (CatG),both of which are highly expressed in the peripheral blood and bone marrow blood of APL.Studies on NE and CatG have found their correlation with the occurrence and development of APL and targeted therapy.This paper reviews the research progress of NE and CatG in APL from the occurrence of APL with NE and the relationship between CatG and APL.

References:

［1］ ZHANG YH,HAN X.Acute promyelocytic leukemia with Chediak-Higashi like giant granules［J］.Blood,2022,139(1):149.
［2］ SANZ MA,FENAUX P,TALLMAN MS,et al.Management of acute promyelocytic leukemia:updated recommendations from an expert panel of the European LeukemiaNet［J］.Blood,2019,133(15):1630-1643.
［3］ XU T,YANG X,JIANG K,et al.Expression of the promyelocytic leukemia protein without the nuclear localization signal as a novel diagnostic marker for acute promyelocytic leukemia［J］.Oncology Reports,2017,37(2):986-994.
［4］ YU L,ZHONG L,XIONG L,et al.Neutrophil elastase-mediated proteolysis of the tumor suppressor p200 CUX1 promotes cell proliferation and inhibits cell differentiation in APL［J］.Life Sciences,2020,242:117229.
［5］ GRIESELHUBER NR,KLCO JM,VERDONI AM,et al.Notch signaling in acute promyelocytic leukemia［J］.Leukemia,2013,27(7):1548-1557.
［6］ LIQUORI A,IBANEZ M,SARGAS C,et al.Acute promyelocytic leukemia:A constellation of molecular events around a single PML-RARA fusion gene［J］.Cancers,2020,12(3):624.
［7］ MANNAN A,MUHSEN IN,BARRAGAN E,et al.Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants［J］.Hematology/Oncology and Stem Cell Therapy,2020,13(4):189-201.
［8］ SAURIN AJ,BORDEN KLB,BODDY MN,et al.Does this have a familiar RING［J］.Trends in Biochemical Sciences,1996,21(6):208-214.
［9］ YANG R,ZHONG L,YANG XQ,et al.Neutrophil elastase enhances the proliferation and decreases apoptosis of leukemia cells via activation of PI3K/Akt signaling［J］.Mol Med Rep,2016,13(5):4175-4182.
［10］ LANE AA,LEY TJ.Neutrophil elastase cleaves PML-RARα and is important for the development of acute promyelocytic leukemia in mice［J］.Cell,2003,115(3):305-318.
［11］ GAO Y,ZHONG L,ZHANG X,et al.PML(NLS-) inhibits cell apoptosis and promotes proliferation in HL-60 cells［J］.International Journal of Medical Sciences,2013,10(5):498-507.
［12］ VECCHIO E,FIUME G,CORRENTI S,et al.Insights about MYC and apoptosis in B-lymphomagenesis:An update from murine models［J］.International Journal of Molecular Sciences,2020,21(12):4265.
［13］ WOLYNIEC K,CHAN A,HAUPT S,et al.Restoring PML tumor suppression to combat cancer［J］.Cell Cycle,2012,11(20):3705-3706.
［14］ MERKL PE,ORZALLI MH,KNIPE DM.Mechanisms of host IFI16,PML,and Daxx protein restriction of herpes simplex virus 1 replication［J］.Journal of Virology,2018,92(10):e00057-18.
［15］ SHAN Z,ZHU X,MA P,et al.PML(NLS-) protein:A novel marker for the early diagnosis of acute promyelocytic leukemia［J］.Molecular Medicine Reports,2017,16(4):5418-5424.
［16］ MEYNIER S,RIEUX-LAUCAT F.FAS and RAS related apoptosis defects:From autoimmunity to leukemia［J］.Immunological Reviews,2019,287(1):50-61.
［17］FERRARA F,MOLICA M,BERNARDI M,et al.Drug treatment options for acute promyelocytic leukemia［J］.Expert Opinion on Pharmacotherapy,2022,23(1):117-127.
［18］ CONSERVA MR,ANELLI L,ZAGARIA A,et al.The pleiotropic role of retinoic acid/retinoic acid receptors signaling:From vitamin A metabolism to gene rearrangements in acute promyelocytic leukemia［J］.Int J Mol Sci,2019,20(12):2921.
［19］ HUYNH TT,SULTAN M,VIDOVIC D,et al.Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells［J］.Scientific Reports,2019,9(1):9414.
［20］ HE B,WANG X,WEI L,et al.β-Cypermethrin and its metabolite 3-phenoxybenzoic acid induce cytotoxicity and block granulocytic cell differentiation in HL-60 cells［J］.Acta Biochim Biophys Sin (Shanghai),2018,50(8):740-747.
［21］ STAHL M,TALLMAN MS.Differentiation syndrome in acute promyelocytic leukaemia［J］.British Journal of Haematology,2019,187(2):157-162.
［22］ HU Z,SAUNTHARARAJAH Y.CEBPE activation in PML-RARA cells by arsenic［J］.Blood,2012,119(9):2177-2179.
［23］ ZAHID MF,KAINTHLA R.Dinner-plate nuclei in hypogranular acute promyelocytic leukemia［J］.Blood,2022,140(23):2519.
［24］ LI J,ZHONG L,YE J,et al.NLS-RARα blocks cell differentiation by inhibiting the retinoic acid signalling pathway［J］.Biochemical and Biophysical Research Communications,2020,528(2):276-284.
［25］ PALMER N,KALDIS P.Less-well known functions of cyclin/CDK complexes［J］.Seminars in Cell & Developmental Biology,2020,107:54-62.
［26］ HEO S,NOH E,GWON G,et al.Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors［J］.European Journal of Pharmacology,2016,789:280-290.
［27］ WANG Y,JIN W,JIA X,et al.Transcriptional repression of CDKN2D by PML/RARα contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells［J］.Cell Death & Disease,2014,5(10):e1431.
［28］ XIONG L,ZHONG L,YU L,et al.NLS-RARα contributes to differentiation block and increased leukemogenic potential in vivo［J］.Cellular Signalling,2020,65:109431.
［29］ LIU SL,LIU Z,ZHANG LD,et al.GSK3beta-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells［J］.Cell Cycle,2017,16(24):2386-2395.
［30］ FOLCO EJ,MAWSON TL,VROMMAN A,et al.Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1α and Cathepsin G［J］.Arteriosclerosis,Thrombosis,and Vascular Biology,2018,38(8):1901-1912.
［31］ BURSTER T,MACMILLAN H,HOU T,et al.Cathepsin G:roles in antigen presentation and beyond［J］.Mol Immunol,2010,47(4):658-665.
［32］ BUSCARLET M,KRASTEVA V,HO L,et al.Essential role of BRG,the ATPase subunit of BAF chromatin remodeling complexes,in leukemia maintenance［J］.Blood,2014,123(11):1720-1728.
［33］ MASHTALIR N,D AVINO AR,MICHEL BC,et al.Modular organization and assembly of SWI/SNF family chromatin remodeling complexes［J］.Cell,2018,175(5):1272-1288.
［34］ ZERNICKEL E,SAK A,RIAZ A,et al.Targeting of BRM sensitizes BRG1 mutant lung cancer cell lines to radiotherapy［J］.Molecular Cancer Therapeutics,2019,18(3):656-666.
［35］ DOMENECH E,GOMEZ-LOPEZ G,GZLEZ-PENA D,et al.New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing［J］.PloS One,2012,7(6):e38158.
［36］ JANCEWICZ I,SIEDLECKI JA,SARNOWSKI TJ,et al.BRM:the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor［J］.Epigenetics & Chromatin,2019,12(1):17-68.
［37］ BIGGS JR,YANG J,GULLBERG U,et al.The human brm protein is cleaved during apoptosis:the role of Cathepsin G［J］.Proceedings of the National Academy of Sciences-PNAS,2001,98(7):3814-3819.
［38］ HOFFMAN GR,RAHAL R,BUXTON F,et al.Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers［J］.Proceedings of the National Academy of Sciences,2014,111(8):3128-3133.
［39］ SHAHMARVAND N,OAK JS,CASCIO MJ,et al.A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia［J］.Int J Lab Hematol,2017,39(4):375-383.
［40］ GHAFFARI H,VARNER JD,PETZOLD LR.Analysis of the role of thrombomodulin in all-trans retinoic acid treatment of coagulation disorders in cancer patients［J］.Theoretical Biology and Medical Modelling,2019,16(1):3.
［41］ FARADAY N,SCHUNKE K,SALEEM S,et al.Cathepsin G-dependent modulation of platelet thrombus formation in vivo by blood neutrophils［J］.PloS One,2013,8(8):e71447.
［42］ COHEN-MAZOR M,MAZOR R,KRISTAL B,et al.Elastase and cathepsin G from primed leukocytes cleave vascular endothelial cadherin in hemodialysis patients［J］.Biomed Res Int,2014,2014:459640.
［43］ SANZ MA,MONTESINOS P.How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia［J］.Blood,2014,123(18):2777-2782.
［44］ VAN DOREN SR.Matrix metalloproteinase interactions with collagen and elastin［J］.Matrix Biology,2015,44-46:224-231.
［45］ KHAN M,CARMONA S,SUKHUMALCHANDRA P,et al.Cathepsin G is expressed by acute lymphoblastic leukemia and is a potential immunotherapeutic target［J］.Frontiers in Immunology,2018,8:1975.
［46］ KELLY A,TROWSDALE J.Genetics of antigen processing and presentation［J］.Immunogenetics (New York),2018,71(3):161-170.
［47］ ZHANG M,SUKHUMALCHANDRA P,ENYENIHI AA,et al.A novel HLA-A*0201 restricted peptide derived from Cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia［J］.Clinical Cancer Research,2013,19(1):247-257.
［48］ ALATRASH G,GARBER HR,ZHANG M,et al.Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target［J］.Leukemia,2017,31(1):234-237.
［49］ HIRANO S,UDAGAWA O,KOBAYASHI Y,et al.Solubility changes of promyelocytic leukemia (PML) and SUMO monomers and dynamics of PML nuclear body proteins in arsenite-treated cells［J］.Toxicology and Applied Pharmacology,2018,360:150-159.

Memo

Memo:
-
Last Update: 1900-01-01